- Home
- IGMS vs ODYS Comparison
IGMS vs ODYS Comparison
Compare IGMS & ODYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- ODYS
- Stock Information
- Founded
- IGMS 1993
- ODYS N/A
- Country
- IGMS United States
- ODYS Israel
- Employees
- IGMS N/A
- ODYS N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- ODYS
- Sector
- IGMS Health Care
- ODYS
- Exchange
- IGMS Nasdaq
- ODYS NYSE
- Market Cap
- IGMS 81.9M
- ODYS 76.7M
- IPO Year
- IGMS 2019
- ODYS N/A
- Fundamental
- Price
- IGMS $1.27
- ODYS $4.62
- Analyst Decision
- IGMS Hold
- ODYS Strong Buy
- Analyst Count
- IGMS 8
- ODYS 1
- Target Price
- IGMS $6.00
- ODYS $10.00
- AVG Volume (30 Days)
- IGMS 1.3M
- ODYS 12.3K
- Earning Date
- IGMS 08-13-2025
- ODYS 08-11-2025
- Dividend Yield
- IGMS N/A
- ODYS N/A
- EPS Growth
- IGMS N/A
- ODYS N/A
- EPS
- IGMS N/A
- ODYS N/A
- Revenue
- IGMS $2,681,000.00
- ODYS $5,842,000.00
- Revenue This Year
- IGMS $252.44
- ODYS N/A
- Revenue Next Year
- IGMS $46.48
- ODYS N/A
- P/E Ratio
- IGMS N/A
- ODYS N/A
- Revenue Growth
- IGMS 27.36
- ODYS 100.27
- 52 Week Low
- IGMS $0.92
- ODYS $4.00
- 52 Week High
- IGMS $22.50
- ODYS $10.80
- Technical
- Relative Strength Index (RSI)
- IGMS 48.73
- ODYS N/A
- Support Level
- IGMS $1.26
- ODYS N/A
- Resistance Level
- IGMS $1.37
- ODYS N/A
- Average True Range (ATR)
- IGMS 0.03
- ODYS 0.00
- MACD
- IGMS -0.01
- ODYS 0.00
- Stochastic Oscillator
- IGMS 8.33
- ODYS 0.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.